In the last trading session, 2.79 million shares of the Neumora Therapeutics Inc (NASDAQ:NMRA) were traded, and its beta was 2.40. Most recently the company’s share price was $1.78, and it changed around -$0.1 or -5.32% from the last close, which brings the market valuation of the company to $287.57M. NMRA currently trades at a discount to its 52-week high of $21.00, offering almost -1079.78% off that amount. The share price’s 52-week low was $1.81, which indicates that the current value has fallen by an impressive -1.69% since then. We note from Neumora Therapeutics Inc’s average daily trading volume that its 10-day average is 1.93 million shares, with the 3-month average coming to 3.03 million.
Neumora Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.44. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended NMRA as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Neumora Therapeutics Inc is expected to report earnings per share of -0.41 for the current quarter.
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
Instantly NMRA has showed a red trend with a performance of -5.32% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.9900 on recent trading dayincreased the stock’s daily price by 10.55%. The company’s shares are currently down -83.21% year-to-date, but still down -4.30% over the last five days. On the other hand, Neumora Therapeutics Inc (NASDAQ:NMRA) is -24.89% down in the 30-day period. We can see from the shorts that 11.03 million shares have been sold at a short interest cover period of 1.84 day(s).
The consensus price target as assigned by Wall Street analysts is $4, which translates to bulls needing to increase their stock price by 55.5% from its current value. Analyst projections state that NMRA is forecast to be at a low of $4 and a high of $4.
Forecasts for the next quarter put sales growth at 0.00%.
Neumora Therapeutics Inc earnings are expected to increase by 55.94% in 2025, but the outlook is positive 25.35% per year for the next five years.
NMRA Dividends
Neumora Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Neumora Therapeutics Inc (NASDAQ:NMRA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 27.47% of Neumora Therapeutics Inc shares, and 66.69% of them are in the hands of institutional investors. The stock currently has a share float of 91.96%.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024 . The former held 2.39 shares worth $4.26 million, making up 1.48% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 2.35 shares worth around $4.18 million, which represents about 1.45% of the total shares outstanding.
